Pierre Fabre Laboratories in the news
global pharmaceuticals, dermocosmetics, French leader
Tamtam found 18 recent articles about Pierre Fabre Laboratories.
- Ali Zeaiter Brings 20 Years of Oncology Experience to Pierre Fabre
Ali Zeaiter, with 20 years of oncology experience, has joined Pierre Fabre Laboratories as Head of Oncology Clinical Development to advance precision oncology initiatives.
- Pierre Fabre, Atara resubmit Ebvallo BLA after two FDA CRLs
Pierre Fabre and Atara Biotherapeutics resubmitted their Biologics License Application for Ebvallo to the US FDA on September 30, 2026, targeting EBV-positive post-transplant lymphoproliferative disease, following two previous FDA rejections.
- Pierre Fabre Pharmaceuticals Resubmits Tabelecleucel Biologics License Application for Treatment of Epstein-Barr Virus Positive-Post-Transplant Lymphoproliferative Disease to the FDA
Pierre Fabre Pharmaceuticals resubmitted its Biologics License Application for tabelecleucel, a treatment for Epstein-Barr virus-positive post-transplant lymphoproliferative disease, to the FDA.
- PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
PhRMA appoints a new CEO, Pierre Fabre Laboratories resubmits Ebvallo for FDA approval, and Mirum Pharmaceuticals reports positive trial results for hepatitis D and gains FDA approval for an FOP drug.
- Laboratoires Pierre Fabre appoints Zombré CEO of U.S. Dermocosmetics operations in Secaucus
Nicolas Zombré has been appointed CEO of Pierre Fabre's U.S. Dermocosmetics operations to accelerate growth and strengthen market position.
- Laboratoires Pierre Fabre Appoints Nicolas Zombré CEO of U.S. Dermocosmetics Business, Signaling Next Phase of Growth
Nicolas Zombré was appointed CEO of Laboratoires Pierre Fabre's U.S. Dermocosmetics business to drive continued growth and market expansion.
- Laboratoires Pierre Fabre Appoints Nicolas Zombré CEO of U.S. Dermocosmetics Business, Signaling Next Phase of Growth
Laboratoires Pierre Fabre appointed Nicolas Zombré as CEO of its U.S. Dermocosmetics business to accelerate growth and strengthen market position.
- Pierre Fabre appoints Venaïg Solinhac as CEO of Dermo-Cosmetics and Personal Care
Pierre Fabre Laboratories appointed Venaïg Solinhac as CEO of its Dermo-Cosmetics and Personal Care division to strengthen global growth and consumer focus.
- Pierre Fabre Invest increases its stake in MiYé to 38 %
Pierre Fabre Invest increased its stake in MiYé to 38%, which will fund expansion of pharmacy networks, healthcare professional prescribers, new product lines, and hiring.
- Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic color
Pierre Fabre Laboratories received a positive CHMP opinion for BRAFTOVI® in combination with cetuximab and FOLFOX for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer, based on strong Phase 3 trial results.
- Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metast
Laboratoires Pierre Fabre secured European Commission approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX, for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer, based on positive Phase 3 trial results.
- Oxurion: Pierre Fabre Adopts Exagis Platform from its Subsidiary Axiodis
Pierre Fabre Laboratories is deploying the Exagis clinical data management platform to improve data collection and regulatory compliance across its trials.
- Oxurion : Pierre Fabre adopte la plateforme Exagis de sa filiale Axiodis
Pierre Fabre Laboratories has implemented the Exagis platform to manage clinical trial data and enhance operational compliance.
- Major market validation: Pierre Fabre Laboratories uses Oxurion's Exagis Platform
Pierre Fabre Laboratories is utilizing Oxurion's Exagis platform to manage its clinical data collection and regulatory compliance across pharmaceutical operations.
- The Eau Thermale Avène brand is pushing Laboratoires Pierre Fabre to accelerate its production – Interview
Pierre Fabre Laboratories is investing 50 million euros to double production capacity at its Avène plant to meet global demand for dermo-cosmetic products.
- Pierre Fabre Laboratories Receives CHMP Positive Opinion For BRAFTOVI Combination In First Line BRAF Mutant Metastatic Colorectal Cancer
Pierre Fabre Laboratories received a positive European regulatory opinion for a new first-line targeted therapy combination to treat metastatic colorectal cancer.
- Pierre Fabre plans to double production capacity at Avène plant in France
A EUR 50 million expansion of the Avène production site will double output to 200 million units to support global skincare demand.
- Pierre Fabre : 50 millions d’euros pour doubler la production de l’usine d’Avène
An investment of 50 million euros will double production capacity at the Avène dermo-cosmetics plant to 200 million units by 2029.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Pierre Fabre Laboratories?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies